The BalancedInvestor Club

VECT Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-2.100.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$1.06BSmall cap

Valuation

Forward P/E
—
PEG ratio
0.00
P/B
3.62
P/S (TTM)
21.08
EV/EBITDA
-5.21

Profitability & growth

ROE (TTM)
-56.9%
Operating margin
-294.5%
Revenue growth YoY
0.0%
Dividend yield
0.0%
Beta
0.10
Last earnings
Nov 29, 2023 · Estimate $-0.46 · Reported $0.00
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 2 · 32 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About VectivBio Holding AG

VectivBio Holding AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of treatments for rare conditions. The company is headquartered in Basel, Switzerland.

Classification

Sector
Healthcare
Industry
Pharmaceuticals
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
AESCHENVORSTADT 36, BASEL, SWITZERLAND
Fiscal year end
December
Latest quarter
Mar 31, 2023
Market cap$1.06B
Shares outstanding$62.8M
52W high$0.00
52W low$0.00

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer